相关临床试验
209
10 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1939
进行中（未招募）
5
2.4%
已完成
122
58.4%
No Longer Available
1
0.5%
尚未招募
5
2.4%
招募中
14
6.7%
暂停
1
0.5%
终止
13
6.2%
Unknown
35
16.8%
撤回
13
6.2%
暂无批准数据
- The FDA held a public hearing on the future therapeutic use of psychedelics, drawing more than 1,800 registered attendees and roughly 80 scheduled speakers. - The hearing followed the agency's July 2026 finalized guidance on psychedelic clinical investigations and an April executive order aimed at accelerating access. - Speakers clashed over provider credentialing, patient safety, rural access, and the need for standardized adverse event and outcome data. - FDA's public docket remains open through October 5, 2026, and written comments will inform continued federal coordination on psychedelic drug development.
- A novel machine learning method called PULSNAR estimated that 7.9% of VHA patients had documented self-harm history, more than four times the 1.85% captured by diagnosis codes alone. - Diagnosis codes captured only about one-fourth of clinically documented self-harm history in a study analyzing electronic health records from over 1.3 million veterans. - Even when self-harm appeared in diagnosis codes, it was missing from problem lists in 77.4% of cases, revealing a critical visibility gap in clinical summaries. - The research tool is not yet ready for clinical use but could eventually help health systems better estimate under-recorded mental health conditions and identify records warranting closer review.
- Cures Within Reach has approved funding for five clinical trials at Chicago-based institutions testing approved therapies for new indications including Parkinson's disease, food allergies, and PTSD. - The trials focus on vulnerable populations including veterans and pediatric patients, with investigations ranging from wearable stimulation devices to chemotherapy drug repurposing. - The nonprofit has expanded its Chicago investment from one trial annually to four or five trials per year, emphasizing support for early-stage investigators affected by 2025 research funding cuts. - CWR's drug repurposing approach leverages existing approved therapies to accelerate treatment development, with the organization currently managing 52 funded trials across 39 institutions globally.
- BioVie will host a virtual KOL event on May 7, 2026, featuring Dr. Suzanne de la Monte to discuss bezisterim's mechanism of action in addressing neurodegenerative disease pathology. - The company's SUNRISE-PD Phase 2 trial is evaluating bezisterim as a monotherapy for motor and non-motor symptoms in Parkinson's patients not treated with carbidopa/levodopa, with topline results expected mid-2026. - Bezisterim is an oral small molecule that crosses the blood-brain barrier and selectively inhibits inflammation-driven ERK and NF-κB pathways while reducing insulin resistance without suppressing immune function. - Previous Phase 2 data showed Parkinson's patients taking bezisterim with levodopa demonstrated better motor control and fewer morning symptoms compared to levodopa alone, with minimal side effects.
- Hoth Therapeutics reports strong safety profile for HT-001 in Phase 2 CLEER-001 trial targeting EGFR-inhibitor-associated rash with no dose-limiting toxicities observed. - The company's HT-KIT program for mastocytosis has received FDA Orphan Drug Designation and is progressing toward IND submission in 2026. - A newly launched GDNF-based metabolic program targeting obesity and hepatic steatosis has initiated studies with the Atlanta VA Medical Center. - The pipeline includes HT-ALZ for Alzheimer's disease advancing through GLP development with positive pharmacokinetic and CNS-penetration modeling.
- A five-year, $18 million Department of Defense clinical trial will investigate metformin's potential to treat idiopathic pulmonary fibrosis, a life-threatening condition with median survival of just three to five years. - The groundbreaking study represents an unprecedented partnership between the VA, DOD, and Pulmonary Fibrosis Foundation, integrating 45-55 care centers with 10 VA medical centers nationwide. - Veterans face higher IPF risk than civilians and have been historically underrepresented in clinical trials, making this collaboration critical for expanding treatment access. - The trial will screen 800 patients and randomize 400 high-risk individuals to receive either metformin or placebo, with enrollment expected to begin in early 2026.
- A large retrospective study of over 161,000 cancer patients across four major U.S. health systems found that COVID-19 booster vaccines reduced hospitalizations and ICU admissions by 29%. - The study showed that boosters prevented one hospitalization or ICU admission for every 150-166 boosted cancer patients, demonstrating significant clinical benefit for this vulnerable population. - Despite the proven effectiveness, booster uptake among cancer patients remained low, with only 68% receiving the original booster and 38% receiving the updated bivalent booster. - The research provides real-world evidence supporting vaccination recommendations for cancer patients, whose immune systems are often compromised by their disease and treatments.
- TrivarX received Institutional Review Board approval to begin a 60-patient clinical trial screening for current major depressive episodes using AI technology in partnership with the US Department of Veterans Affairs. - The trial will test whether TRI's AI algorithm can effectively detect mental health conditions through sleep data using single-channel ECG technology compatible with wearable devices like smartwatches. - Previous Phase 2 studies demonstrated promising results with 87% sensitivity and 67% specificity in identifying current major depressive episodes, potentially addressing the growing mental health crisis that has seen claims surge from $1.2 billion to $2.2 billion between 2019-2024.
- The FDA has granted 510(k) clearance to Bright Uro's Glean™ Urodynamics System, the first wireless, catheter-free device for monitoring bladder dysfunction in patients with lower urinary tract conditions. - The innovative system addresses limitations of conventional urodynamic testing by eliminating painful catheters and enabling natural voiding during normal daily activities for more accurate diagnostic data. - Cleveland Clinic became the first institution to use the device clinically, marking the culmination of over a decade of research collaboration between Cleveland Clinic, Case Western Reserve University, and Louis Stokes Cleveland VAMC. - The technology targets an estimated 80 million Americans suffering from voiding problems including overactive bladder, urinary incontinence, enlarged prostate, and neurogenic bladder.
- A study at AHA 2024 reveals that pharmacists in the VHA system, when given feedback on heart failure medication rates, increased their management and adjustment of these medications. - The audit and feedback intervention led to a significant increase of 1.2 more visits per month and more heart failure medication adjustments by pharmacists. - Monthly audit and feedback emails notably increased the frequency of prescribing mineralocorticoid receptor antagonists, a historically under-prescribed heart failure medication. - Access to patient-specific information did not significantly improve outcomes beyond the benefits of audit and feedback alone.
